The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on‐off fluctuations.

British Journal of Clinical Pharmacology

Volumn 22, Issue 4, 1986, Pages 429-436

  Hardie, RJ ^a   Malcolm, SL ^a   Lees, AJ ^a   Stern, GM ^a   Allen, JG ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPA; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CARBOXYLYASE; LEVODOPA;

CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ON OFF PHENOMENON; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PHARMACOKINETICS; PRIORITY JOURNAL; THERAPY;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; CARBOXY-LYASES; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; KINETICS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RANDOM ALLOCATION; TYROSINE;

EID: 0022451735     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1986.tb02913.x     Document Type: Article

References (21)

1. The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism
2. l‐dopa level in plasma, primary condition for the kinetic effect
3. Senile Parkinsonism and dopa pharmacokinetics
4. Amino acid precursors of monoamine neurotransmitters and some factors influencing their supply to the brain
5. Levodopa pharmacokinetics: Alterations after benserazide, a decarboxylase inhibitor
6. Gastric emptying rate and the systemic availability of levodopa in the elderly Parkinsonian patient
7. ELSMOS. An Extended Least Squares Modelling System in Fortran IV for Minicomputer Implementation
8. On‐off fluctuations in Parkinson's disease. A clinical and neuropharmacological study
9. Parkinsonism: Onset progression and mortality
10. A comparison of the effects of reversible and irreversible inhibitors of aromatic l‐amino acid decarboxylase on the half‐life and other pharmacokinetic parameters of oral l‐3,4‐dihydroxyphenylalanine
11. The metabolism of l‐3‐O‐methyl dopa, a precursor of dopa in man
12. Protein intake and treatment of Parkinson's disease with levodopa
13. Plasma dopa concentrations after different preparations of levodopa in normal subjects
14. The ‘on–off’ phenomenon in Parkinson's disease. Relation to levodopa absorption and transport
15. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of Parkinsonism
16. l‐methionine: a possible levodopa antagonist
17. Bioavailability of marketed levodopa preparation in dogs and Parkinsonian patients
18. The impact of treatment with levodopa on Parkinson's disease
19. Variability of l‐dopa absorption in man
20. 3‐OMe dopa uptake and inhibition of l‐dopa at the blood‐brain barrier
21. Active transport of L‐dopa in the intestine